LoginSign Up
Rodin Therapeutics

Rodin Therapeutics

Rodin Therapeutics is a biotechnology company developing treatments for Alzheimer's disease that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Ankit Mahadevia and Martin Jefson.

Rodin Therapeutics is a biotechnology company developing therapies for neurological disorders by applying insights gained from epigenetics. The company was founded by Ankit Mahadevia and Martin Jefson in 2013, and is headquartered in Cambridge, Massachusetts.

Funding

Seed round

On June 27, 2013 Rodin Therapeutics closed their seed funding round with an undisclosed amount of funding from Johnson & Johnson Development Corporation and Atlas Venture.

Series A

On May 29, 2014 Rodin Therapeutics closed their series A funding round raising $12.9 million is funding from Johnson & Johnson Development Corporation and Atlas Venture.

Series B

On January 6, 2016 Rodin Therapeutics closed their series B funding round raising $17.3 million in funding from Biogen Idec and Atlas Ventures.

Series C

On September 18, 2017 Rodin Therapeutics closed their series C funding round raising $27 million in funding from Third Point Ventures, Remeditex Ventures, Hatteras Venture Partners, GV, and Atlas Ventures. In addition to closing their series C funding round Rodin Therapeutics appointed three new members to their Board of Directors.

Timeline

People

Name
Role
Related Golden topics

Ankit Mahadevia

Founder

Bruce Booth

Founder

Further reading

Title
Author
Link
Type

Oryzon Genomics Develops Epigenetic Treatment for Alzheimer's

Alexander Burik

News

Trial to Test New Imaging Agent for Visualizing Synapses in Living Brain

Patricia Inacio

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References